ArticleOncogene2005
Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Review
- Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase.BMB reports · 2019Review
- MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering.Oncotarget · 2017Article
- Genome-wide association of multiple complex traits in outbred mice by ultra-low-coverage sequencing.Nature genetics · 2016Article
- Biology of MET: a double life between normal tissue repair and tumor progression.Annals of translational medicine · 2015Review
- Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.Annals of translational medicine · 2015Review
- Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.Current pharmaceutical design · 2013Article
- The Lsktm1 locus modulates lung and skin tumorigenesis in the mouse.G3 (Bethesda, Md.) · 2012Article
- Cancer genes in lung cancer: racial disparities: are there any?Genes & cancer · 2012Article
- The role of the c-Met pathway in lung cancer and the potential for targeted therapy.Therapeutic advances in medical oncology · 2011Article
- The MET axis as a therapeutic target.Update on cancer therapeutics · 2009Article
- C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.Cancer biology & therapy · 2008Article
- c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.Current oncology reports · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Analysis of seven candidate genes mapping in the 1-Mb region of the mouse pulmonary adenoma resistance 4 (Par4) locus revealed a single amino-acid change, consisting in a nonconservative Arg968Cys variation in the juxtamembrane domain of the Met proto-oncogene-encoded protein. The BALB/c strain (resistant allele) carried the Arg allele, whereas the SWR/J mouse strain (Par4-susceptible allele) carried the Cys variation, recently proven to functionally modulate tumorigenesis. Seven genetic linkage crosses herein analysed and six crosses reported in the literature pointed to the candidacy of the Met gene for Par4. Analysis of genomic DNA of 126 lung adenocarcinoma patients for the Met juxtamembrane domain revealed the same Arg/Cys variation at the mouse homologous position in one patient; two other patients carried additional variants in the same domain, suggesting a potential role for rare MET juxtamembrane variants in human lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.